The EUR-CART project as a prototype model for AR T cell immunotherapy in Europe. Eur. J. Immunol. 48, 216–219 (2018). Article CAS Google Scholar Ramos, C. A. et al. Anti-CD30 CAR T cell therapy in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol. 38, 3794–3804 (...
Anti-CD19 CAR T-cell therapy(Sheba Medical Center): 一种CD19抑制剂药物,由Sheba Medical Center公司最早进行研发,目前全球最高研发状态为临床3期,作用机制: CD19抑制剂(B淋巴细胞抗原CD19抑制剂),治疗领域: 肿瘤,在研适应症: 急性髓性白血病,在研机构: Sheba Medi
Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusdoi:10.1038/s41591-022-02091-9Nature Publishing Group USNature Medicine
Thus, therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy. This is a preview of subscription content, access via your institution Access ...
anti-CAR清除CAR-T细胞 2010年,在第一代自体CD19 CAR-T治疗中,2例滤泡型淋巴瘤患者体内,CAR-T持续时间未能超过1周。重新输注更高剂量CAR-T且同时使用IL-2,依旧无法在体内存活。究其原因,除了制造工艺之外(第一代CAR鼠源成分较高),第一次输注引起针对CAR的免疫反应,导致了第二次输注细胞无法存活。
Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrome (CRS) and neurotoxicity, impeding their therapeutic application. Here we generated a new anti-CD19 CAR molecule (CD19-BBz(86)) derived from the CD19-BBz prototype bearing co-stimulatory 4-1...
In general, the TME suppresses T-cell recruitment, further blocking CAR T cell activity and facilitating survival of lymphoma cells. In order to overcome the resistance mechanisms of anti-CD19 CAR T therapy, novel promising agents have been introduced in combination with CAR T therapy, ICIs, TKI...
We treated 20 patients with B-cell lymphoma on a phase I, first-in-human clinical trial of T cells expressing the new anti-CD19 CAR Hu19-CD828Z (NCT02659943). The primary objective was to assess safety and feasibility of Hu19-CD828Z T-cell therapy. Secondary objectives included ...
Stealth transgenes enable CAR-T cells to evade host immune responses. PMID: 38724463 Preparation and characterization of a chimeric CD19 monoclonal antibody. PMID: 1725979 Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. PMID: 33023981 ...
Recently published data from the ZUMA-1 and JULIET trials suggest that CD19-directed chimeric antigen receptor (CAR) T cell therapy can provide durable remissions, with a low risk of relapse or progression, in 30鈥?0% of patients with relapsed and/or refractory aggressive large B cell lymphoma...